[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Western University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":225},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,39,70,107,132,158,181,201],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100640036",false,"NCT07580976","Tru-Vu Wrist Positioning Aid Multi-Center Implementation Within NLHS","Inclusion Criteria:\n\n* Must be 18 years of age or older\n* Must be proficient in English (reading\u002Fwriting)\n* Must have been referred for wrist imaging at one of the following healthcare centers: Health Sciences Center (St. John's, NL), Bonne Bay Health Center (Norris Point, NL), or Labrador Health Center (Happy Valley-Goose Bay, NL).\n\nExclusion Criteria:\n\n* Incapable of providing informed consent","ALL","18 Years",{"count":17,"type":18},1800,"ESTIMATED","INTERVENTIONAL",[21],"PHASE3","This study has two primary aims: 1) to determine whether a novel wrist x-ray positioning aid can be implemented within 3 different healthcare centers in Newfoundland and Labrador, and 2) to determine the ability of the tool to improve patient positioning in wrist x-rays. It will also learn about the number of repeat x-rays required with or without the use of the tool and radiographer confidence. The main questions it aims to answer are:\n\n1. Will the implementation of the Tru-Vu differ between an urban health center, rural clinic, and remote regional hospital?\n2. Can the Tru-Vu improve the positioning procedure for radiographers performing wrist x-rays, resulting with more useful x-rays.\n\nResearchers will compare x-rays before and after the implementation of the tool as well as between centers.\n\nTechnologist participants will:\n\n* Use the tool during the positioning procedure for wrist x-rays.\n* Provide feedback regarding tool use and perceived implementation barriers and facilitators.",[24,25],"Trauma (Including Fractures)","Arthritis","NOT_YET_RECRUITING","2026-05-13",{"date":29,"type":30},"2026-05-18","ACTUAL",{"date":32,"type":18},"2026-06-14",{"date":34,"type":18},"2027-09-01",{"name":36,"class":37},"Western University","OTHER",3,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":10,"sex":14,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":19,"phases":48,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100623871","NCT07402265","Piloting a Brief, Online Intervention for Suicidality in Sexual and Gender Minority Youth","Inclusion Criteria:\n\n* Resident of Canada\n* Fluent in English\n* Youth (i.e., 13-25 years)\n* Identifies as a sexual and\u002For gender minority (i.e., any sexual identity excluding heterosexual and\u002For any gender identity excluding cisgender)\n* Endorses experiencing any suicidal ideation within the past 6 months\n* Access to a computer and able to participate virtually\n\nExclusion Criteria:\n\n* Does not meet the inclusion criteria","13 Years","25 Years",{"count":47,"type":18},250,[49],"NA","Sexual and gender minority youth (i.e., LGBTQ+ individuals) are at elevated risk for suicidal thoughts compared to cisgender\u002Fheterosexual youth and there is increased demand for programs and treatments tailored to this population. The current study seeks to pilot a brief, online, self-guided intervention for suicidal thoughts designed for sexual and gender minority youth to test if this intervention is acceptable to this population and if completing this intervention significantly decreases suicidal thoughts.",[52,53,54],"Suicidal Thoughts","Sexual and Gender Minorities","Youth",[56,53,54,57,58,59,60,61],"Suicidal thoughts","Brief","Online","Self-Guided","Self-Compassion","Self-Neutrality","2026-02-06",{"date":64,"type":30},"2026-02-11",{"date":66,"type":18},"2026-02-01",{"date":68,"type":18},"2026-09-30",{"name":36,"class":37},{"id":71,"slug":4,"hasResults":10,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":10,"sex":76,"minAge":15,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":19,"phases":79,"briefSummary":81,"conditions":82,"keywords":90,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100500889","NCT05802121","Akkermansia Muciniphilia and Metabolic Side Effects of ADT","The Role of Akkermansia Muciniphilia in Combating the Metabolic Effects of Androgen Deprivation Therapy in Men With Metastatic Prostate Cancer","For inclusion in this study, patients must fulfill all of the following criteria:\n\n1. Men ≥18 years of age with histologically-proven metastatic castration-sensitive prostate adenocarcinoma planned to receive ADT (TNM stage Tany, Nany, M1) (see Appendix I).\n2. Must have baseline imaging with 1) CT of the abdomen, and pelvis and bone scan or 2) PSMA PET scan\n\nPatients fulfilling any of the following criteria are NOT eligible for participation in this study:\n\n1. Age less than 18\n2. Primary neuroendocrine prostate cancer\n3. Treatment with ADT within the year leading up to enrolment\n4. Planned or concurrent use of chromium supplementation for the study duration\n5. Planned or concurrent use of apple cider vinegar supplementation for the study duration\n6. Unable to provide informed consent or unable to understand or read the English language (unless accompanied by an interpreter)\n7. Inadequate liver function (\\>2x upper limit of normal)\n8. Any other condition, chronic disease, or lifestyle factor, that, in the opinion of the Qualified Investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant\n9. Use of antibiotics that cannot be discontinued for a washout period and remain off them for the duration of the trial","MALE",{"count":78,"type":18},30,[80],"EARLY_PHASE1","The overriding objectives of this study are:\n\n1. Primary outcomes:\n\n   1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to a standard of care arm.\n   2. To confirm tolerability and assess for side effects of oral acetate supplementation.\n2. Secondary outcomes:\n\n   1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.",[83,84,85,86,87,88,89],"Prostate Cancer","Metabolic Syndrome","Obesity","Cardiovascular Morbidity","Bone Diseases","Hyperlipidemias","Diabetes",[91,92,93,94,95,96],"prostate cancer","metabolic syndrome","androgen deprivation therapy","microbiome","Akkermansias muciniphilia","cardiovascular disease","RECRUITING","2025-08-15",{"date":100,"type":30},"2025-08-20",{"date":102,"type":30},"2025-07-02",{"date":104,"type":18},"2027-06",{"name":36,"class":37},1,{"id":108,"slug":4,"hasResults":10,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":10,"sex":14,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":19,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100598028","NCT07066163","SMART-PD: Evaluating the Impact of Smartphone-Based Wearable Technology on Motor Symptoms and Quality of Life in People With Parkinson's Disease","SMART PD","Inclusion criteria:\n\n* Meet criteria for Parkinson's disease using MDS Clinical Diagnostic Criteria for Parkinson's Disease\n* Presence of Motor fluctuations based on movement disorder neurologist assessment.\n* Motor ability to use the wearable device and access the wearable device application.\n* Cognitively ability to do ADL's and use the wearable device and access the wearable device application based on clinician's judgment.\n* Knowledge of English to enter medication details in the wearable device application.\n\nExclusion criteria:\n\n* Physical barriers in using the wearable device.\n* Atypical Parkinsonian disorder or other causes of Parkinsonism\n* Inability to read or write English.","40 Years",{"count":115,"type":18},32,[49],"This study aims to evaluate whether wearable technology can improve the management of motor symptoms in people with Parkinson's disease (PD) who experience motor fluctuations throughout the day. The project will use a smartwatch and mobile app (KinesiaU) to continuously track movement, allowing for more responsive and personalized treatment compared to traditional monitoring methods.\n\nIn this pilot randomized controlled trial, 32 participants will be assigned to either:\n\nA control group receiving standard care, or\n\nA wearable device group receiving standard care plus using the smartwatch.\n\nOutcomes will be assessed over a 4-week period, focusing on changes in motor function, quality of life, and self-management. The study will also examine feasibility, adherence, and data quality.\n\nIf successful, this trial will provide critical evidence for integrating wearable devices into routine clinical care for PD, paving the way for larger efficacy trials and more patient-centered care strategies.",[119],"Parkinson Disease, Idiopathic",[121,122],"parkinson","wearable","2025-07-03",{"date":125,"type":30},"2025-07-15",{"date":127,"type":18},"2026-01",{"date":129,"type":18},"2029-05",{"name":36,"class":37},2,{"id":133,"slug":4,"hasResults":10,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":10,"sex":14,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":19,"phases":140,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":4},"100595539","NCT07033767","Exploring a Natural Solution for Childhood Obesity","Inclusion Criteria:\n\n* Children and adolescents aged 4-17 years.\n* Obesity defined as a BMI z-score ≥ 2 for age and sex, based on World Health Organization (WHO) reference standards.\n* Stable or increasing BMI after at least 3 months of enrollment in the HEAL program.\n* Inclusion of participants from all backgrounds, consistent with principles of equity, diversity, and inclusion.\n* Participants and families who do not speak or read English will be included, provided interpreter services are available at LHSC's Children's Hospital.\n* Participants who decline to enroll will continue receiving standard care in the HEAL program.\n\nExclusion Criteria:\n\n* Known allergy to Sophora japonica (source of genistein).\n* Diagnosis of type 2 diabetes (these patients are followed in a separate Diabetes Clinic).\n* Current use of medications that may confound study outcomes, including:\n* GLP-1 receptor agonists (e.g., Saxenda, Wegovy)\n* ADHD medications (e.g., Concerta, Vyvanse, Abilify)\n* Antipsychotic medications (e.g., Risperidone)\n* Currently pregnant, breastfeeding, or planning to become pregnant during the study period.","4 Years","17 Years",{"count":78,"type":18},[141,142],"PHASE1","PHASE2","This study aims to assess the safety tolerability, adherence and effectiveness of genistein as an anti-obesity treatment for children and adolescents. The primary goal is determining how well genistein is tolerated and adhered to by pediatric patients with obesity. Secondary goals include evaluating its impact on body mass index z-scores and cardiometabolic risk factors, such as inflammation.\n\nParticipants aged 4-18 will be recruited from the Paediatric HEAL (Healthy Eating, Activity \\& Lifestyle) Program at the Children's Hospital - London Health Science Center in London, Ontario. They will receive genistein treatment over 6 months, with interim assessments at 3 and 6 months to monitor efficacy, safetytolerability, and adherence, and efficacy, and potentially increase the dose at the 3-month visit. A final assessment will occur after a 3-month washout to observe any lasting effects.\n\nBlood and urine samples will be collected to analyze various adherence and health markers, including inflammatory and cardiometabolic factors. For participants who are of childbearing potential and have had their first menses, the blood analysis will also include pregnancy testing. Laboratory testing will be performed at baseline, at three and six months while taking genistein and three months after the washout period. Urine samples will also confirm that genistein has been taken appropriately throughout the study.\n\nThe study expects that genistein will be well-tolerated by children, reduce BMI z-scores by 0.2 (0.5), and improve cardiometabolic risk factors such as blood pressure, lipid profiles, and inflammation. A sample size of 60 participants has been calculated to achieve statistically significant results, which will inform more extensive studies on genistein's potential for managing pediatric obesity.",[85,145],"Children",[147,148,149],"genistein","childhood obesity","children","2025-06-19",{"date":152,"type":30},"2025-06-24",{"date":154,"type":18},"2025-08-01",{"date":156,"type":18},"2026-12",{"name":36,"class":37},{"id":159,"slug":4,"hasResults":10,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":164,"sex":14,"minAge":165,"maxAge":138,"enrollmentInfo":166,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":106},"100499173","NCT05779813","Genetic Frontotemporal Dementia Initiative for Neurodevelopment","GENFI-NeuroDev","Inclusion Criteria:\n\n1. Written informed consent must be obtained and documented (from the participant and their substitute decision maker). This can be obtained in person or remotely.\n2. Youths between the ages of 9 and 16 inclusive at time of enrollment, followed until age 17.\n3. Youths must have a 1st or 2nd degree biological relative who has participated (past or present) in the Genetic Frontotemporal Dementia Initiative (GENFI) study or with genetic FTD (i.e. a known mutation in biological parent or grandparent).\n4. Parent(s)\u002Fguardian deem appropriate to participate.\n5. Must have a study partner who can participate as required in the protocol (provide corroborative information). Study partner must have regular contact with the participant and must be parent\u002Fguardian of this participant.\n6. Must have age-appropriate awareness that FTD runs in their family as determined by local PI.\n\nExclusion Criteria:\n\n1. Current structural brain abnormality affecting cognition or behaviour not thought to be possibly related to genetic FTD that would prevent completion of study assessments (such as brain tumor, stroke, hydrocephalus).\n2. Other concerns that participation in the study may not be in the best interest of the youth or parent, as raised by the participant's parent\u002Fguardian\u002Fprimary care provider, local site PI or psychologist.\n3. Lack of study partner.\n4. For MRI: meeting any MRI incompatible criteria. Note: Participants may opt to decline MRI scans and complete the other measures.",true,"7 Years",{"count":167,"type":18},200,"OBSERVATIONAL","This is an international multi-centre cohort study of first and second degree family members of individuals who carry Frontotemporal Dementia (FTD) mutations in MAPT, GRN or C9ORF72 repeat expansions for youths between the ages 9-17.",[171,172],"Frontotemporal Dementia","Family Members","2025-03-31",{"date":175,"type":30},"2025-04-03",{"date":177,"type":30},"2023-03-31",{"date":179,"type":18},"2035-03",{"name":36,"class":37},{"id":182,"slug":4,"hasResults":10,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":10,"sex":14,"minAge":113,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":19,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100580409","NCT06836921","WECARE APD: Assessing a Single Multidisciplinary Team Visit for Atypical Parkinsonian Disorders","WECARE APD: Randomized Trial to Evaluate the Impact of a Single Multidisciplinary Team Visit for Atypical Parkinsonian Disorders: a Feasibility Study","WECARE APD","Inclusion Criteria (Participants must meet all of the following conditions to be eligible for the study):\n\n* Participants must be older than 40 years.\n* The participant must meet the standard international consensus criteria for a clinically probable diagnosis of one of the following neurodegenerative conditions:Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP);Cortico-Basal Syndrome (CBS)\n\nExclusion Criteria (Participants will be excluded if they meet any of the following conditions):\n\n* Severe Physical or Cognitive Limitations:\n\n  * Participants must be able to attend the clinic.\n  * Individuals with severe physical disabilities or cognitive impairments that prevent clinic attendance will be excluded.\n* Life-Threatening Comorbidities:\n\n  * Participants with severe, advanced medical conditions that significantly impact survival or functional ability will be excluded. These include, but are not limited to:End-stage renal disease (ESRD) requiring dialysis; End-stage congestive heart failure (CHF) with severe functional impairment; Advanced malignancy (such as metastatic cancer or terminal cancer with limited prognosis).\n* Living in long-term care, away from the care-partner",{"count":78,"type":18},[49],"Atypical Parkinsonian disorders (APD) are a group of brain disorders that look like Parkinson's disease but progress faster and don't respond well to common treatments like levodopa. These conditions include Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), and Multiple System Atrophy (MSA). Caring for APD patients is especially challenging because the symptoms worsen quickly and require multiple specialists, often leading to separate visits with different doctors and therapists. This not only increases the burden on patients and caregivers but also results in high medical costs. Despite the serious impact of APD, there is no proven care model that significantly improves the quality of life for patients and their caregivers.\n\nTo address this, the investigator team has created a novel type of clinic that brings together a team of specialists in a shared appointment to provide comprehensive care in one visit. This study aims to test whether an early visit with this team, in addition to regular medical care, can improve quality of life, help patients manage their symptoms better, and reduce the stress on caregivers. The investigators will conduct a six-month study with two groups: one will receive the multidisciplinary care visit right away, while the other will continue with regular care and receive the visit after six months. Patients and caregivers will fill out questionnaires about their well-being at the beginning, after one month, and after six months. The study will also measure how practical it is to run this type of clinic, making sure enough people participate, complete the required surveys, and stay in the study.\n\nThis will be the first study to test whether a team-based care model is practical and beneficial for APD patients and their caregivers. If successful, it could serve as a foundation for larger studies and potentially improve care for other complex neurological conditions in the future.",[192],"Parkinson Plus","2025-02-15",{"date":195,"type":30},"2025-02-20",{"date":197,"type":18},"2025-03-15",{"date":199,"type":18},"2026-07-20",{"name":36,"class":37},{"id":202,"slug":4,"hasResults":10,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":19,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":106},"100549030","NCT06428708","[18F] PSMA-1007 PET\u002FCT in Metastatic Clear Cell Renal Cell Carcinoma","Comparison of [18F] PSMA-1007 PET\u002FCT and Conventional Imaging in the Detection of Metastatic Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Men and women with histologically-proven, metastatic renal cell carcinoma (RCC)(TNM stage Tany, Nany, M1)\n2. Must have baseline conventional imaging of the chest, abdomen, and pelvis with contrast-enhanced CT or MRI within 5 weeks of enrolment. Contrast is required unless the participant cannot for medical reasons (ie renal failure).\n\nException: Unenhanced CT of the chest is acceptable Exception: Unenhanced MRI of abdomen and pelvis is acceptable in cases of renal failure\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. Age less than 18\n3. Histology does not have any clear cell component\n4. Unable to lie flat for 30 minutes for the scan\n5. History of prior malignancy (except non-melanoma skin cancer)\n6. Unable to provide informed consent\n7. Inadequate liver function\n8. Systemic or radiation-based cancer treatment is needed urgently and anticipated to begin before PSMA scan can take place\n9. Previously exposed to systemic or radiation cancer therapy (except radiation for skin cancer)",{"count":78,"type":18},[80],"Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.",[211],"Metastatic Clear Cell Renal Cell Carcinoma",[213,214,215,216],"PSMA PET","Metastatic clear cell renal cell carcinoma","[18F]PSMA-1007","PSMA","2024-06-22",{"date":219,"type":30},"2024-06-25",{"date":221,"type":30},"2022-01-24",{"date":223,"type":18},"2025-09",{"name":36,"class":37},""]